MARKET

JAZZ

JAZZ

Jazz Pharmaceuticals Plc
NASDAQ
165.50
+2.35
+1.44%
After Hours: 165.50 0 0.00% 17:56 02/06 EST
OPEN
164.16
PREV CLOSE
163.15
HIGH
166.62
LOW
164.16
VOLUME
703.38K
TURNOVER
--
52 WEEK HIGH
182.99
52 WEEK LOW
95.49
MARKET CAP
10.06B
P/E (TTM)
-27.2666
1D
5D
1M
3M
1Y
5Y
1D
How HERIZON-GEA’s First-Line GEA Data And sBLA Plan At Jazz Pharmaceuticals (JAZZ) Has Changed Its Investment Story
Simply Wall St · 1d ago
Rigel Pharmaceuticals Appoints Michael P. Miller to Board of Directors
Reuters · 4d ago
Harmony Biosciences Makes The Grade
Seeking Alpha · 5d ago
Weekly Report: what happened at JAZZ last week (0126-0130)?
Weekly Report · 6d ago
Is Jazz Pharmaceuticals (JAZZ) Offering Opportunity After A 32% One Year Share Price Gain
Simply Wall St · 01/31 18:20
ALX Oncology announces new data from Phase 1b/2 trial of evorpacept, Ziihera
TipRanks · 01/30 13:35
ALX Oncology Data From Phase 1b/2 Clinical Study Of CD47-Inhibitor Evorpacept In Combination With Jazz Pharmaceuticals' ZIIHERA Demonstrates CD47 Expression Is Predictive Of Evorpacept Activity
Benzinga · 01/30 13:18
ALX Oncology Reports CD47 Biomarker Predicts Response to Evorpacept in Advanced HER2-Positive Breast Cancer
Reuters · 01/30 13:15
More
About JAZZ
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.

Webull offers Jazz Pharmaceuticals PLC stock information, including NASDAQ: JAZZ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JAZZ stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JAZZ stock methods without spending real money on the virtual paper trading platform.